Recruiting
Phase 1

SNV1521 & RAS

Sponsor:

ParVation Therapeutics, Inc.

Code:

NCT07756281

Conditions

Pancreatic Cancer

Pancreatic Acinar Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

SNV1521

daraxonrasib

Study Details

Brief summary:

This study is a Phase 1 clinical trial testing an oral investigational drug called SNV1521 together with a RAS-targeted cancer medicine in people with pancreatic cancer that cannot be removed by surgery or has spread. The main goals are to find doses of the drug combination that are safe and tolerable and to look for early signs that the treatment may help control the cancer. Participants will receive the study medicines in repeating cycles and will have regular blood tests, scans, and other exams to monitor side effects and how their cancer responds.

Conditions

Pancreatic Cancer

Pancreatic Acinar Carcinoma

Study ID

NCT07756281

Start date

Sep 1, 2026

Status verified date

Oct, 2026

Completion date

Jun 1, 2029

Anticipated

Primary completion date

Jun 1, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Adults (18 years and older).
  • Diagnosis of pancreatic cancer that cannot be removed by surgery or has spread to other parts of the body.
  • Cancer confirmed by tissue or cell examination (histology or cytology).
  • At least one measurable tumor on scans.
  • Good enough general health and organ function to receive study treatment, as judged by the study doctor.
  • Able to swallow oral medicines.
  • Willing to follow study visit schedule and contraception requirements.

Exclusion Criteria:

  • Serious heart, lung, liver, or other medical problems that would make study treatment unsafe.
  • Active, uncontrolled infections.
  • Other active cancers that could interfere with study assessments (except certain early-stage cancers that have been treated).
  • Prior treatments or medicines that are not allowed by the protocol (for example, some strong drug interactions).
  • Known brain or nervous system involvement from the cancer that is not stable or controlled.
  • Pregnant or breastfeeding, or unwilling to use required birth control during and after the study.

Study Design

Enrollment

40 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Escalation

Participants in this arm will take SNV1521 by mouth together with a RAS-targeted cancer medicine. The dose of SNV1521 will be increased in small steps to find a safe and tolerable dose of the combination in people with advanced pancreatic cancer.

Interventions

SNV1521

SNV1521 is an oral investigational anticancer drug. In this study, SNV1521 is administered at different dose levels together with the RAS inhibitor daraxonrasib in adults with locally advanced unresectable or metastatic pancreatic cancer.

daraxonrasib

Daraxonrasib is an oral targeted cancer medicine used in this study together with SNV1521. It is given once daily to help evaluate the safety and tolerability of the drug combination in people with advanced pancreatic cancer.

Primary outcome measure

  • Safety and tolerability of SNV1521 plus daraxonrasib: treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities [ Time Frame: through study completion, an average of 1 year ]

Central Contacts and Locations

Central contacts

Kevin O'Hayer

919-451-6590kohayer@synnovationtx.com

Locations

MD Anderson

Recruiting

Houston, Texas, United States, 77030

Contacts

Tim Yap

1-844-785-0306, option 1PhysicianReferrals@MDAnderson.org

Principal Investigator:

Tim Yap

More Information

Sponsor

ParVation Therapeutics, Inc.

Last update posted

Oct 27, 2026

Last verified

Oct, 2026

Keywords

  • daraxonrasib
  • PARP
  • pancreas
  • pancreatic cancer

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-28. This information was provided to ClinicalTrials.gov by ParVation Therapeutics, Inc. on 2026-10-27. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.